Figure 7
Targeting the fatty acid synthesis pathways reduces tumor growth in the CWR22-RV1-derived CRPC model. (a) CWR22-RV1 cells (in absence of androgen) were treated with statin or Triacsin C (purchased from Cayman Chemical) (0–50 μM) for 6d, followed by flow cytometry cell counting. (b, c) CWR22-RV1 cells were stably infected by lenti-viral shRNA against ELOVL7 (shELOVL7, purchased from Dharmacon) or non-target control (shNTC) with or without 10 nM DHT, followed by (b) qRT-PCR for ELOVL7 and (c) immunoblotting for ELOVL7. (d) CWR22-RV1 cells stably expressing shNTC or shELOVL7 were subcutaneously injected into castrated male SCID mice (N=6, age ~6 weeks). The first measurement of tumor volume was at ~2 weeks after injection. The statistical analysis was done using student’s t-test and the sample size was estimated based on power analysis. After the mice were sacrificed at 15d, the xenograft tumors were extracted and shown.
